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Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside 
analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer. A hallmark of chronic hepatitis B is a dysfunc-
tional HBV-specific T-cell response. We therefore designed an immunotherapy driven by naive healthy T cells specific for the HDV 
antigen (HDAg) to bypass the need for HBV-specific T cells in order to prime PreS1-specific T cells and PreS1 antibodies blocking 
HBV entry.
Methods. Ten combinations of PreS1 and/or HDAg sequences were evaluated for induction of PreS1 antibodies and HBV- and 
HDV-specific T cells in vitro and in vivo. Neutralization of HBV by PreS1-specific murine and rabbit antibodies was evaluated in cell 
culture, and rabbit anti-PreS1 were tested for neutralization of HBV in mice repopulated with human hepatocytes.
Results. The best vaccine candidate induced T cells to PreS1 and HDAg, and PreS1 antibodies blocking HBV entry in vitro. 
Importantly, adoptive transfer of PreS1 antibodies prevented, or modulated, HBV infection after a subsequent challenge in human-
ized mice.
Conclusions. We here describe a novel immunotherapy for chronic HBV/HDV that targets viral entry to complement NAs and 
coming therapies inhibiting viral maturation.
Keywords.  chronic hepatitis B; immunotherapy; PreS1 antibodies; T-cell tolerance; hepatitis D antigen.
Despite preventive vaccines and antiviral therapies, chronic 
hepatitis B virus (HBV) infection currently affects over 250 
million people across the globe [1]. One million chronic 
carriers die every year due to the liver-related complica-
tions caused by HBV, such as liver cirrhosis and eventually 
hepatocellular carcinoma (HCC) [2–4]. The hepatitis D virus 
(HDV), an RNA satellite virus to HBV that “steals” the surface 
antigen from HBV (HBsAg), coinfects 15–25 million of the 
HBV carriers globally and worsens disease progression [3, 5]. 
As yet, there is no effective functional cure for chronic HBV 
or HDV infection. The current standard of care therapy for 
HBV consists of nucleoside analogues (NAs) that inhibit the 
reverse transcriptase (RT) function of HBV polymerase. This 
prevents viral maturation by blocking the synthesis of the par-
tially double-stranded DNA inside the capsid [6]. Thus, NAs 
only suppress the viral replication during therapy. This is due 
to the fact that blocking RT neither affects protein production 
(including HBsAg) and release, nor synthesis of the covalently 
closed circular DNA, the main cause of HBV persistence [7]. 
Life-long NA therapy reduces, but does not eliminate, the risk 
of HCC [8, 9]. At least 1-year pegylated interferon-α (IFN-α) is 
the currently recommended treatment for chronic HDV; how-
ever, sustained response rates are low [3, 10]. Combination 
treatment with pegylated IFN-α and NAs has been shown to 
have limited efficacy against HDV [11] and HBV [12].
HBV uses several strategies in order to evade the host immune 
response. The chronic presence of HBV proteins induces a T-cell 
dysfunction [13–17]. HBV-infected cells overproduce subviral 
HBsAg particles, mainly containing small HBsAg [18], to block the 
neutralizing antibody population directed to small HBsAg [19]. 
This ensures survival of viral particles whose surfaces are denser 
in the middle HBsAg (containing S and PreS2) and large HBsAg 
(containing S, PreS2, and PreS1) proteins [18, 20]. Importantly, the 
PreS1 domain is responsible for binding to the Na+-taurocholate 
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cotransporting polypeptide (NTCP) receptor for HBV on hep-
atocytes [21, 22]. Thus, an obvious way to target infectious HBV 
particles and prevent the infection of new hepatocytes would be to 
raise antibodies to the PreS1 domain of the virus.
To build an immunotherapy targeting both infections able 
to induce PreS1 antibodies and T cells to HBV and HDV we 
generated chimeric genes containing PreS1 and the large HDV 
antigen (HDAg) in different combinations (Figure 1). The ad-
vantage of linking PreS1 to HDAg is that HDAg will act as a 
heterologous T-cell epitope carrier in patients monoinfected 
by HBV [21, 22]. Thus, these HDAg-specific T cells support 
a sustained endogenous production of PreS1 antibodies that 
block viral entry and bypass the need for HBV-specific T cells. 
In fact, >90% of HBV carriers are monoinfected with HBV [5], 
and in these the heterologous HDAg will prime healthy naive T 
cells that support priming of HBV-specific responses. In addi-
tion, it is likely the HDAg-specific T cells and PreS1 antibodies 
may also prevent HDV superinfection in these patients. To in-
duce both neutralizing antibodies and T cells, we used genetic 
immunization, as this strategy has been shown to activate im-
mune responses to HBV [23–25]. Overall, this virus entry-
blocking strategy complements the maturation inhibitors and 
capsid assembly inhibitors currently under development [26, 
27] in order to achieve sustainable off-therapy responses.
METHODS
Animals
Female C57BL/6 (H-2b) mice were obtained from Charles River 
Laboratories, Sulzfeld, Germany. HLA-A2 transgenic HHD 
mice were bred inhouse. All mice were 8–10 weeks old at the 
start of the experiments and maintained under standard con-
ditions at Preclinical laboratory (PKL), Karolinska University 
Hospital Huddinge, Sweden. uPA+/+-SCID mice with hu-
manized liver were produced as previously described [28, 29] 
and maintained at the central animal facility of the Faculty of 
Medicine and Health Sciences, Ghent University. New Zealand 
White rabbits were purchased from commercial vendors and 
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Figure 1. Vaccine design, analysis of expression of HBV/HDV proteins from vaccine constructs, and therapy concept. A, A total of 10 vaccine constructs (D 1–10) were 
designed containing HBV and HDV sequences according to the design concept (B). C, The DNA vaccine candidates were characterized by direct western blot for their ability 
to be translated into the expected proteins of interest (arrow heads). The gene constructs consisted of different combinations of PreS1A/B consensus sequences linked to 
the HDAg of genotype 1 and/or genotype 2 from 4 different clinical isolates (A/B, genotype 1; C/D, genotype 2). The self-cleaving peptide P2A (approximately 10k Da) was 
included in some of the constructs for cleavage of the fusion proteins at different loci of PreS1A/B-HDAg sequences to test if and how this affects the functionality of the 
constructs. Depending on where the P2A cleaved the fusion proteins, bands of the respective fragments corresponded to the expected size range (ie, HDAg genotype 1 A/B at 
47 kDa, HDAg genotype 2 C/D at 47 kDa, PreS1A/B at 10 kDa, and P2A at 10 kDa). Bands at around 50 kDa are nonspecific (ns). GFP was used as negative control. Detailed 
analysis of each construct and the sizes of the respective fragments are given in Supplementary Table 1. Abbreviations: GFP, green fluorescent protein; HBV, hepatitis B virus; 
HDAg, HDV antigen; HDV, hepatitis D virus.
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kept at Astrid Fagreus Facility at Karolinska Institute. All an-
imal procedures were approved by local ethical committees for 
animal research in Sweden and Belgium.
DNA Plasmids
Plasmids encoding genotypes 1 and 2 of the L-HDAg and the 
PreS1 domain (aa 2–48) of the HBsAg were used in this study 
as fusion constructs, consisting of different combinations of 
HDAg/PreS1 sequences cleaved by P2A (Figure 1). The HDAg 
sequences of genotypes 1 and 2 were obtained from 4 different 
clinical isolates: US-2 and CB, and 7/18/83 and TW2476, re-
spectively. All genes were cloned into the pVAX1 backbone 
(Invitrogen) using restriction sites EcoRI and HindIII. Plasmids 
were grown in TOP10 Escherichia coli cells (Life Technologies) 
and purified for in vivo injections using Qiagen Endofree DNA 
purification kit (Qiagen) following manufacturer’s instructions. 
The correct gene size was confirmed by restriction enzyme 
digests using EcoRI and HindIII (Fast Digest; Thermo Fisher 
Scientific).
Western Blot
Western blot was essentially performed as described previously 
[30, 31]. Hela cells were transfected with each pVAX1 D  1-10 
DNA plasmid and pVAX1 with the reporter gene green fluores-
cent protein (GFP) as control (Figure  1), using Lipofectamine 
3000 Transfection Reagent (Thermo Fisher Scientific). For pro-
teins detection, serum from the D4 vaccinated rabbit diluted 
1:1000 (primary antibody) and goat anti-rabbit immunoglobulins 
HRP 0.25g/L (DAKO) diluted 1:4000 (secondary antibody) were 
used. For chemiluminescence detection, Pierce ECL Plus Western 
Blotting Substrate was used and images were collected with the 
Gel Doc XR+ system (Biorad) (Supplementary Material).
Peptides
A total of 168 HDAg 15mer peptides with 10 amino acid (aa) 
overlap were purchased from Sigma-Aldrich. The 168 pep-
tides were divided in 8 pools each containing 20 or 21 peptides 
(Supplementary Table 2). Four pools corresponded to geno-
type 1 (pool 11–21, pool 222–42, pool 343–63, and pool 464–84) and 4 
pools corresponded to genotype 2 (pool 11–21, pool 222–42, pool 
343–63, and pool 464–84) for sequences A, B, C, and D, with each 
sequence referring to each clinical isolate.
Two consensus sequences of the PreS1 HBsAg (PreS1A and 
PreS1B) consisting of 47 aa and 20mer PreS1peptides with 10 
aa overlap for HBV (sub) genotypes A1, A2, B, B2, C, D1, E1, 
and F (Supplementary Table 3) were purchased from Sigma-
Aldrich. All peptides passed quality control (Sigma-Aldrich 
PEPscreen Directory) and had purity >70%. OVA 257–264 CTL 
(SIINFEKL) and OVA 323–339 Th (ISQAVHAAHAEINEAGR) 
were used as negative peptide controls, while concanavalin 
A (Sigma Aldrich) was used as a positive control at final con-
centration 0.5μg/μL.
Immunization Protocols for Evaluating Immunogenicity of HBV/HDV 
Plasmids in Mice and Rabbits
To evaluate the immunogenicity of the constructs in vivo, mice 
and rabbits were immunized essentially as described [25, 30–
32], boosted at monthly intervals, and sacrificed 2 weeks later 
for spleens and blood collection. In brief, female C57BL/6 mice 
(5 per group) were immunized intramuscularly in the tibialis 
cranialis anterior muscle with 50 μg plasmid DNA in a volume 
of 50 μL in sterile phosphate-buffered saline (PBS) by regular 
needle (27G) injection followed by in vivo electroporation 
using a Cliniporator 2 device (IGEA). During in vivo electropo-
ration a 1-ms 600-V/cm pulse followed by a 400-ms 60-V/cm 
pulse pattern was used to facilitate better uptake of the DNA. 
Prior to vaccine injections, mice were given analgesic and kept 
under isoflurane anesthesia during the vaccinations. For studies 
in rabbits, 2 New Zealand White rabbits per group were im-
munized with 900 μg D3 and D4 DNA vaccines. Vaccines were 
administered by intramuscular injection in 300 μL sterile PBS 
to the right tibialis cranialis anterior muscle followed by in vivo 
electroporation.
Detection of IFN-γ–Producing T Cells by Enzyme-Linked Immunospot Assay
Two weeks after the last vaccination, splenocytes from each im-
munized group of mice were pooled (5 mice/group) and tested 
for their ability to induce HBV/HDV-specific T cells based on 
IFN-γ secretion after peptide stimulation for 48 hours as de-
scribed previously [25, 30, 31] using a commercially available 
enzyme-linked immunospot (ELISpot) assay (Mabtech).
Antibody Detection by ELISA
Detection of mouse and rabbit immunoglobulin G (IgG) against 
PreS1 consensus and overlapping 20mer peptides (10 μg/mL) 
was performed following a previously described protocol [32]. 
Antibody titers were determined as endpoint serum dilutions at 
which the OD value at 405 nm was at least twice the OD of the 
negative control (nonimmunized or control animal serum) at 
the same dilution.
Neutralization Effect of PreS1 Antibodies by an HBV In Vitro Assay
HepG2-NTCP-A3 is a selected cell clone derived from the 
HepG2 cell expressing human NTCP as described previously 
[22]. It was cultivated in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal calf serum, 2 mM l-glutamine, 50 
U/mL penicillin, and 50 μg/mL streptomycin. During and after 
inoculation, 2.5% dimethyl sulfoxide (DMSO) was added to the 
medium to enhance HBV infection and replication. HBV virus 
stock used for infection was prepared from HepAD38 cells by 
PEG precipitation as described [33]. Cell culture media between 
day 3 and 6 postinfection were collected and diluted 1:5 with 
PBS for enzyme-linked immunosorbent assay (ELISA) analysis 
of hepatitis B e antigen (HBeAg) quantification using commer-
cial antibodies (Fitzgerald) as described previously [34].
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HBV Neutralization Assay in Human Liver–uPA-SCID Mouse Model
IgG antibodies were purified (Pierce Protein A kit; Thermo 
Fisher Scientific) from D4-vaccinated rabbit serum and 
concentrated (Amicon Ultra device; Millipore) at a final 
concentration of 50  mg/mL as determined spectrophoto-
metrically at 280  nm. A  total of 15  mg vaccine-induced 
IgG and IgG from nonimmunized rabbit was administered 
to human liver chimeric uPA-SCID mice [29, 35]. Three 
days after intraperitoneal administration of IgG, mice 
were challenged with an HBV dose of 106 IU/mouse. DNA 
levels were measured at weeks 1, 2, 3, 4, 6, and 8 using the 
Abbott RealTime HBV assay (Abbott Laboratories) to de-
tect whether IgG administration could protect against HBV 
infection.
Statistical Analysis
Data was analyzed using GraphPad Prism v.5 and v.8 software 
and Microsoft Excel v.16.13.1.
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Figure 2. HBV/HDV IFN-γ–secreting T cells are genotype specific. Graphs show the mean number of IFN-γ–secreting cells per million for 4 representative vaccinated mice 
groups with D1–D4 constructs after stimulation with the respective antigens, as determined by ELISpot. Each color corresponds to the respective sequences of the constructs 
shown in Figure 1 (ie, green, HDAg genotype 1; orange, HDAg genotype 2; blue, PreS1 A/B). Mice were sacrificed 6 weeks after first immunization and pooled splenocytes 
from each group were stimulated for 48 hours with the HDV peptide pools 1–8 corresponding to genotype 1 (pools 1–4) and genotype 2 (pools 5–8). Pools 1 and 2 of geno-
type 1 refer to sequence/isolate A while pools 3 and 4 correspond to sequence/isolate B. Similarly, for HDV genotype 2, pools 5 and 6 refer to sequence/isolate C and pools 
7 and 8 to sequence/isolate D (Supplementary Table 2). Each pool contained 20 or 21 (for pools 1 and 5) 15mer peptides with 10-aa overlap. PreS1A and PreS1B peptides 
refer to the consensus sequences (total 47 aa; region 2–48 aa) while OVA CTL and OVA Th (1 μg/mL) were negative controls. ConA (0.5 μg/mL) was a positive control. Each 
peptide-stimulated group was run in triplicate and bars show the mean number of IFN-γ SFC per 106 cells with standard error. Cutoff was set at 100 SFCs/106 splenocytes. 
Abbreviations: aa, amino acid; ConA, concanavalin A; ELISpot, enzyme-linked immunospot; gpt, genotype; HBV, hepatitis B virus; HDAg, HDV antigen; HDV, hepatitis D virus; IFN-γ, 
interferon-γ; SFC, spot forming cell. 
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RESULTS
Expression Products of HBV/HDV Plasmids
The 10 different HBV/HDV plasmids were correctly trans-
lated into the predicted proteins in vitro as confirmed by direct 
western blot (Figure 1 and Supplementary Table 1).
Immunization With HDAg Induces Genotype-Specific T Cells
Vaccine primed HDV-specific T cells secrete high levels of 
IFN-γ in an HDAg genotype-specific pattern as determined 
by ELISpot, shown in Figure  2 and Supplementary Figure 1. 
In addition, strong T-cell responses to PreS1 were also seen 
(Figure  2). Notably, in D3 and D4-treated groups a slight re-
duction in HDV T-cell responses was observed compared to 
constructs that contained only HDAg (D5, D6, D9, and D10; 
Supplementary Figure 1), which might be attributable to epi-
tope recognition competition with the simultaneous priming of 
PreS1-specific T cells. Overall, this shows that active immuni-
zation is able to induce functional T cells to PreS1 and HDAg 
antigens and suggests that a broadly functional immunotherapy 
should contain both HDV genotypes 1 and 2 to ensure induc-
tion of specific T cells.
DNA Immunization Induces Broadly Cross-Reactive PreS1 Antibodies and 
HLA-A2–Restricted T Cells
The ability of the candidate immunotherapies to induce PreS1 
antibodies was determined in sera from immunized mice and 
rabbits. Antisera were tested for reactivity against PreS1A 
and PreS1B consensus peptides (aa 2–48) and for cross-reac-
tivity against HBV (sub) types A1, A2, B, B2, C, D1, E1, and F 
using pools of 20mer PreS1-peptides (Supplementary Figure 
2 and Figure3). As shown in Figure 3, the DNA plasmids ex-
pressing constructs D3 and D4 induced antibody titers >104 
in mice, and lower titers with constructs D1, D2, D7, and D8. 
Importantly, antisera from D4 and D7 immunized mice effec-
tively cross-reacted with all tested HBV types (Supplementary 
Figure 2). The data from the D3 and D4 immunized rabbits 
followed the same pattern, with the D4 plasmid inducing 
antibodies >103 (Figure 3C and 3D).
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Figure 3. Detection of PreS1-specific IgG by ELISA. IgG antibodies from 6-week vaccinated mouse and rabbit sera were measured by ELISA, as previously described [32]. 
All 10 DNA constructs (D 1–10) were tested for IgG antibodies against (A) PreS1A and (B) PreS1B 2-48 amino acid consensus sequences in mice (5 mice per group); only 
constructs containing PreS1 were further evaluated for cross-reactivity against HBV (sub) genotypes A1, A2, B, B2, C, D1, E1, and F (Supplementary Figure 2). Similarly, rab-
bits (2 per group) were vaccinated with D3 and D4 DNA constructs and 6 weeks after first immunization sera were collected and tested by ELISA against (C) PreS1A and (D) 
B consensus peptides. The vaccinated rabbit antisera were also tested for cross-reactivity to HBV (sub) genotypes A1, A2, B, B2, C, D1, E1, and F (Supplementary Figure 3). 
Bars show the mean anti-PreS1 titers for each group, determined as the last serum dilution giving an OD 405nm 3 times higher than the OD of nonimmunized sera at the 
same dilution. Sera were titrated serially with 6-fold dilutions starting at 1:60. A and B, Mean ± SD from 2 independent experiments. C and D, Mean from 1 representative 
experiment. Abbreviations: ELISA, enzyme-linked immunosorbent assay; HBV, hepatitis B virus; HDV, hepatitis D virus; IgG, immunoglobulin G.
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The fine specificity of the rabbit D4 antisera was determined 
using individual 20mer PreS1 peptides of HBV types A1, A2, 
B, B2, C, D1, E1, and F (Supplementary Table 3 and Figure 4). 
This mapped the epitopes to PreS1 region 22–48 aa of geno-
type D1, as indicated by the higher reactivity, with lower reac-
tivity to genotypes C, E1, and A1 (Figure 4). This overlaps with 
the NTCP binding site and partly with previously identified 
epitopes recognized by neutralizing antibodies [36]. Finally, im-
munization of HLA-A2 Tg mice with D4 induced “human-like” 
HLA-A2–restricted T cells (Figure 4).
PreS1 Antibodies From Immunized Mice and Rabbits Neutralize HBV 
In Vitro
Sera from immunized mice obtained 2 weeks (mice) and 6 
weeks (mice and rabbits) after first immunization were tested 
for ability to prevent HBV infection of HepG2 cells expressing 
Human NTCP (Figure  5 and Figure  6A). Neutralization of 
HBV was determined by detection of secreted HBeAg in cul-
ture supernatants. The immunogens D3 and D4 induced the 
strongest neutralizing antibodies (Figure  5), suggesting that 
these PreS1 antibodies indeed block HBV entry. In rabbits, 
only the D4 plasmid induced cross-reactive PreS1 antibodies 
(Figure  3), and we noted that anti-PreS1 levels by ELISA of 
>103 were required for achieving in vitro neutralization of HBV 
(Figure 6A).
Neutralization of HBV Infection In Vivo in Humanized Mice
The ability of D4-induced antibodies to neutralize HBV infec-
tion in vivo was determined using the human liver chimeric 
uPA-SCID mouse model, as described [29, 35]. Total IgG was 
purified from D4-immunized and nonimmunized rabbits and 
injected in uPA-SCID mice repopulated with human hepato-
cytes 3  days prior to HBV challenge. The D4-induced PreS1 
IgG antibodies protected, or significantly delayed, peak viremia 
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in all challenged mice (Figure 6). Of 3 challenged mice, 1 was 
protected (weeks 1 to 3) whereas the other 2 developed serum 
levels of HBV <104 IU/mL up to 4 weeks postchallenge and re-
mained lower compared to the controls at 8 weeks postchallenge 
(Figure  6B). The control mice treated with IgG from a naive 
rabbit all reached serum HBV DNA levels exceeding 108 IU/
mL (Figure 6). There were no significant differences between 
the groups with respect to serum levels of alanine transferase, 
asparagine transferase, alkaline phosphatase, or bilirubin 
(Supplementary Figure 4). In conclusion, passive immunization 
with D4-specific PreS1 IgG antibodies given as a single dose was 
able to prevent, or significantly delay, HBV infection in vivo in 
mice repopulated with human hepatocytes. Importantly, the in-
oculum contained high levels of subviral particle small HBsAg, 
showing that these antibodies indeed escaped being blocked by 
small HBsAg. The PreS1 antibodies present at inoculation and 
during the first weeks clearly block infection, or the first rounds 
of infection, and limit the number of infected hepatocytes. This 
limits the viral spread and delays development of peak viremia.
DISCUSSION
The current antiviral treatments for chronic HBV and HDV 
infections using NAs or other small molecules can effectively 
suppress the viral load during ongoing therapy and slow down 
disease progression, but do not fully prevent development of 
liver disease [4, 9]. None of these compounds effectively in-
duce a functional cure, especially when targeting the immune-
tolerant chronic carrier [12, 37]. A functional cure is defined as 
the stable loss of HBsAg in serum. New therapeutic strategies 
are needed that overcome, or circumvent, the immune evasion 
strategies exerted by the virus and stimulate the host to control 
the infection and induce a functional cure [38].
We therefore designed an immunotherapy targeting an ad-
ditional step of the viral life cycle to improve off-therapy re-
sponses. The therapy was designed with 2 main considerations: 
(1) to block HBV and HDV infection by stimulating endoge-
nous PreS1 receptor-blocking antibody production; and (2) to 
avoid using large HBV sequences, as T cells to HBV antigens are 
highly dysfunctional in chronic HBV. To recruit healthy T cells 
that do not cross-react with dysfunctional HBV-specific cells in 
patients with chronic HBV, we used HDAg as a heterologous 
T-cell carrier. Because >90% of HBV carriers are not coinfected 
by HDV [5], the HDAg-specific T cells are, in the vast majority 
of HBV carriers, as naive and healthy as those in as naive and 
healthy as T cells to any other HBV-unrelated heterologous car-
rier antigen [30]. However, these HDV-specific T cells can still 
be relevant for HDV and thus an HBV monoinfected carrier 
may become immune to HDV superinfection through PreS1-
HDAg–based vaccination. Thus, using HDAg as a carrier for 
PreS1 sequences serves multiple purposes.
Using a genetic vaccine that contains PreS1 and HDAg, we 
can induce endogenous production of PreS1 antibodies that 
block the PreS1-mediated entry of HBV using the receptor 
NTCP [39]. PreS1 is only a minor component on subviral 
particles that cause the immune dysfunction but it is vital 
for the infectivity of HBV particles [18, 20, 40]. Therefore, 
the PreS1-specific antibodies efficiently avoid being blocked 
by the circulating subviral particles and can neutralize HBV 
[19]. To test our concept described above, we generated 10 
different DNA plasmids as immunogens containing various 
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Figure 5. In vitro neutralization against HBV from 2-week (A) and 6-week (B) vaccinated mouse antisera. All the vaccinated mouse antisera (D 1–10) were evaluated for 
their functionality by an in vitro neutralization assay against HBV on HepG2 cells expressing Human NTCP. Quantification of HBV infection was determined by measuring 
secreted HBeAg using ELISA, presented as relative infectivity (% HBeAg). Standard curve was generated from HBV infected but untreated (negative control) group diluted 
with phosphate-buffered saline. All groups vaccinated with constructs containing PreS1 showed neutralization activity at 2 weeks after first immunization (A) while the D4 
vaccine construct had the strongest neutralization effect as indicated by the lowest relative infectivity at 6 week, followed by construct D3 (B). All samples from both week 
2 and week 6 time points were run at the same time and Myrcludex B (60 μM) was used as positive control in the assay. Abbreviations: HBeAg, hepatitis B e antigen; HBV, 
hepatitis B virus; ELISA, enzyme-linked immunosorbent assay; NTCP, Na+-taurocholate cotransporting polypeptide.
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combinations of PreS1 and/or HDAg sequences. These were 
tested for induction of specific antibodies and T cells to iden-
tify the most immunogenic design. The DNA constructs 
induced strong PreS1 and HDV T-cell responses. The HDAg-
specific T cells were genotype specific in mice of 2 different 
genetic backgrounds (Figure 2 and data not shown). Thus, to 
avoid a potential T-cell nonresponder status in humans, we 
selected constructs carrying 2 strains of HDAg corresponding 
to the 2 major genotypes of HDV. The constructs combining 
PreS1 and HDAg sequences effectively induced high levels of 
PreS1 antibodies in both mice and rabbits. PreS1 antibodies 
from both species were highly cross-reactive against different 
HBV types and subtypes. The most immunogenic design, 
which raised potent HBV/HDV-specific T-cell responses in 
wild-type and HLA-A2 transgenic mice and high anti-PreS1 
titers, comprised HDAg sequences of 2 genotypes coupled to 
tandem PreS1 sequences. Importantly, we could demonstrate 
that the antibodies induced by these active immunogens were 
also the most effective at neutralizing HBV in vitro, using a 
well-established assay that efficiently supports the full viral life 
cycle [22, 33]. We were then interested in determining whether 
these entry-blocking anti-PreS1 antibodies could inhibit HBV 
infection of human hepatocytes in vivo. From the studies in 
rabbits, it was evident that antibody levels >103 to PreS1, as 
determined by ELISA, neutralized HBV in vitro. We therefore 
purified total IgG from D4 immunized and nonimmunized 
rabbits and evaluated these antibodies for protection against 
HBV infection in a mouse model repopulated with human 
hepatocytes [35]. We found that a single injection of these 
antibodies indeed protected, or limited, HBV infection in vivo 
over a 3 to 8-week period. The reduced levels in 2 mice were 
most likely due to a limited first round infection and neutral-
ization over the first weeks from challenge. Thus this delayed 
the development of peak HBV viremia. We therefore con-
cluded that a D4 DNA-based immunotherapy protects human 
hepatocytes against HBV infection both in vitro and in vivo.
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There are currently different approaches in development 
aiming at inhibiting HBV entry and these are mainly based either 
on PreS1-derived peptides or antibodies targeting the S or PreS1/2 
domains of HBsAg. PreS1 antibodies are known to neutralize 
HBV [41]. The most advanced approach in clinical development 
so far is a PreS1 peptide-based competitive inhibitor termed 
Myrcludex B, which has been successful in blocking entry of 
mainly HDV, but also HBV [42]. This peptide, however, requires 
daily subcutaneously administration for 12–24 weeks to reach op-
timal antiviral effects in patients with chronic HDV and/or HBV. 
Also, although it can successfully prevent HDV/HBV entry by 
competitively binding to NTCP, alterations in the bile acid trans-
port and metabolite functions of the receptor have been noted [43, 
44]. PreS1-peptide–based vaccines have also been shown to be 
able to break immunotolerance in chronic HBV carrier mice, sup-
porting its important therapeutic role in controlling HBV infec-
tion [45]. Other strategies in the pipeline are therapeutic vaccines 
containing different versions of HBV antigens [46]. Although, it 
has been shown that vaccines containing only HBV sequences can 
be safe and occasionally elicit T-cell responses in chronic HBV 
carriers [23, 24], it still remains unclear if they can overcome, or 
restore, the T-cell dysfunction of the infected host and, thus, be of 
clinical benefit [47]. It is likely that additional immunologic trig-
gers are needed to activate the host’s immune responses [48, 49]. 
We therefore aimed at raising endogenously produced antibodies 
against the PreS1 antigen using PreS1 sequences linked to HDAg. 
Here, HDAg acts as a heterologous T-cell epitope carrier that cir-
cumvents, or bypasses, the engagement and dependence on the 
dysfunctional HBV-specific T-cell response present in a chroni-
cally infected host. As an added benefit, the immunized chronic 
carriers monoinfected with HBV can become immune against an 
HDV superinfection.
In conclusion, we have designed a new immunotherapy ap-
proach for HBV and potentially HDV. Our design concept aims 
at circumventing the major hurdles in the infected host, such 
as overexpression of antigens that block neutralizing antibodies 
and the profound T-cell dysfunction/tolerance. Here, HDAg 
serves as a healthy heterologous T- and B-cell carrier to circum-
vent the engagement of dysfunctional HBV-specific T cells in 
the induction of PreS1 antibodies. We show induction of T cells 
specific for PreS1 and HDAg and antibodies that block HBV 
entry into hepatocytes in vitro and in vivo. The concept of by-
passing T-cell tolerance will be further assessed in the context of 
a chronic carrier model. This approach, with the host as the pro-
ducer of the entry inhibitors, may, in combination with existing 
and coming maturation inhibitors, achieve durable off-therapy 
responses and a functional cure for chronic HBV infection.
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Diseases online. Consisting of data provided by the authors to 
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